News

In the wake of a sharp decline in sales of its blockbuster arthritis drug, Remicade, MSD is to offer the NHS discounts and rebates amounting to £48 million on £191 million sales, announced medical affairs director Colin Wheeler last week.

Organiser PharmaTimes Media is delighted to announce the launch of the 2016 edition of its annual competition for clinical researchers in the Americas.

In the wake of a sharp decline in sales of its blockbuster arthritis drug, Remicade, Merck & Co – known as MSD in the UK – is to offer the NHS discounts and rebates amounting to £48 million on £191 million sales, announced medical affairs director Colin Wheeler last week.

The interim report for the long-awaited Accelerated Access Review has been published, laying out the plans for speeding up access to innovative drugs in the UK.

Although most of the UK population is proud of the NHS, older people living with multiple long-term conditions believe the health and care system is not set up to deliver their needs, according to NHS tracking data.

A cheap, off-patent Alzheimer’s drug could have previously-unnoticed benefits in the late stages of the disease and save the NHS money, according to new research.

In the wake of a sharp decline in sales of its blockbuster arthritis drug, Remicade, Merck is to offer the NHS discounts and rebates amounting to £48 million on £191 million sales, announced medical affairs director Colin Wheeler last week.

The largest study of the genetics of testicular germ cell tumours has uncovered four new genetic variants associated with increased risk of testicular cancer – the most common cancer in young men.

The Precision Medicine Catapult has announced the initial locations for its regional centres of excellence network. 

Seasonal flu immunisation rates are down on last year despite the government’s new pharmacy vaccination scheme, according to new figures from Public Health England.

New data for Merck’s Keytruda suggests that the immunotherapy can improve survival in patients with advanced non-small cell lung cancer (NSCLC) who expressed PD-L1, potentially allowing the company to update the drug’s label.

Medical experts in the US have called for value-based pricing to curb ‘outrageous’ drug costs that are ‘bankrupting’ patients.

Annual data from the Home Office has shown a 6% drop in the number of animals used for scientific experimentation in UK labs.

With more than 30 major pharma companies and comms agencies taking part in this year’s PharmaTimes Marketer & Communications Team of the Year competition, it is a must-attend event for pharma industry professionals.

The National Institute for Health and Care Excellence has published final draft guidelines recommending four drugs to treata form of arthritis in children and young people.